Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer

The authors described the design and development of third-generation mutant-selective EGFR inhibitors with improved in vitro and in vivo profiles and lower toxicities during administration to patients than those of previously disclosed second-generation furanopyrimidine EGFR inhibitors.